Management of Elevated Vancomycin Trough Levels

Assessment and Monitoring

A trough level of 21 mg/L is above the recommended therapeutic range of 15-20 mg/L for complicated infections such as bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia 1, 2
Sustained trough concentrations >20 μg/mL increase the risk of nephrotoxicity 3
The elevated level indicates a need for dosage adjustment to reduce the risk of vancomycin-induced nephrotoxicity 3
Measure a repeat trough level before administering the next dose to confirm the level has decreased to the target range 1
Monitor serum creatinine closely for signs of nephrotoxicity, defined as multiple (at least 2-3 consecutive) increases in serum creatinine of 0.5 mg/dL or 150% increase from baseline 3

Hold the next scheduled dose of vancomycin and recheck the trough level before administering subsequent doses 3
Once the trough level decreases to the target range (15-20 mg/L), resume vancomycin at a reduced dose or with an extended dosing interval 3, 4
For patients with normal renal function, consider reducing the dose by approximately 15-20% or extending the dosing interval 4

The target AUC/MIC ratio is ≥400 for most patients with MIC ≤1 mg/L 2
Individual pharmacokinetic adjustments are recommended rather than relying solely on nomograms 1

Continuing the same dosage despite elevated trough levels, which increases nephrotoxicity risk 3
Monitoring only peak levels, which is not recommended and provides limited clinical value 3
Discontinuing vancomycin therapy completely when still clinically indicated, rather than adjusting the dose 4
Failing to consider alternative therapies when vancomycin MIC is ≥2 mg/L, as target AUC/MIC ratios may not be achievable with conventional dosing 2

Patients with vancomycin trough levels significantly above the therapeutic range (15-20 μg/mL) and evidence of acute kidney injury should be considered for dialysis, according to the Infectious Diseases Society of America 5
Patients with an increase in serum creatinine ≥0.5 mg/dL or a 150% increase from baseline after several days of vancomycin treatment should be considered for dialysis, as recommended by the Infectious Diseases Society of America 6
The use of concomitant nephrotoxic agents increases the risk of requiring dialysis, as stated by the Infectious Diseases Society of America 6
Prolonged treatment with vancomicina increases the risk of requiring dialysis, according to the Infectious Diseases Society of America 6
Obesity or alterations in volume of distribution increase the risk of requiring dialysis, as reported by the Infectious Diseases Society of America 7
Sustained trough concentrations >20 μg/mL increase the risk of requiring dialysis, as recommended by the Infectious Diseases Society of America 6

Monitoring vancomycin trough levels regularly during treatment is recommended by the Infectious Diseases Society of America to prevent toxicity 6
Avoiding sustained trough concentrations >20 μg/mL is recommended by the Infectious Diseases Society of America to prevent toxicity 6
Considering alternative therapeutic options in patients at high risk of nephrotoxicity is recommended by the Infectious Diseases Society of America 7

The Infectious Diseases Society of America recommends obtaining the initial vancomycin trough level before the fourth or fifth dose to ensure steady-state conditions have been reached 8, 9, 10
Pre-dose (trough) monitoring is the most accurate and practical method for guiding vancomycin dosing, according to the Infectious Diseases Society of America 8

For serious infections, such as bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin/soft tissue infections, the Infectious Diseases Society of America recommends trough monitoring with target levels of 15-20 mg/L 8, 9, 10
Trough monitoring is mandatory for patients with morbid obesity, renal dysfunction, fluctuating volumes of distribution, and those receiving treatment duration >7 days, as stated by the Infectious Diseases Society of America 8, 9, 10

For serious infections with MIC ≤1 mg/L, the Infectious Diseases Society of America recommends targeting an AUC/MIC ratio ≥400, and considers a loading dose of 25-30 mg/kg in critically ill patients to rapidly achieve therapeutic levels 8, 9, 11
The Infectious Diseases Society of America advises against using vancomycin when MIC ≥2 mg/L (VISA/VRSA), as target AUC/MIC ratios are not achievable, and recommends switching to alternative therapy 8, 9, 10